To give an example, TD52, an erlotinib analogue, was found to prevent the binding of Elk1 to the CIP2A promoter, resulting in decreased CIP2A transcription in hepatocellular carcinoma [95]. This evidence concerns the gene CIP2A and hepatocellular carcinoma.